MedTrace Logo

Dietary Intervention for Migraine Relief

NCT07360405 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-22

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary glutamate intake may influence processes involved in migraine, such as brain excitation, inflammation, and oxidative stress.

The main questions this study aims to answer are:

Does following a low-glutamate diet reduce the number of migraine days and the severity and duration of migraine attacks, and improve quality of life?

Are improvements in migraine symptoms associated with changes in blood-based biological markers related to migraine activity?

Researchers will compare participants assigned to the low-glutamate diet with participants assigned to a wait-list control group to evaluate differences in migraine outcomes and related biological measures.

Participants will:

Complete a baseline run-in period while tracking headaches using a daily migraine diary

Either follow a low-glutamate dietary intervention or continue their usual diet as part of a wait-list control

Complete standardized questionnaires related to migraine symptoms and quality of life

Provide blood samples for laboratory analyses

Undergo neuroimaging assessments (for a subset of participants)

Conditions

Interventions

BEHAVIORAL

Dietary training

Subjects will undergo a 2-hour online training session to teach them how to follow the low glutamate diet. The low glutamate diet is a healthy, whole-food diet designed to limit the intake of free glutamate/aspartate, while also emphasizing the consumption of foods which are high in nutrients that protect against glutamate excitotoxicity and oxidative stress.

Sponsors & Collaborators

  • Georgetown University

    collaborator OTHER

  • American University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07360405 on ClinicalTrials.gov